Details for Patent: 7,157,456
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,157,456 protect, and when does it expire?
Patent 7,157,456 protects XARELTO and is included in two NDAs.
Protection for XARELTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-four patent family members in forty-six countries.
Summary for Patent: 7,157,456
Title: | Substituted oxazolidinones and their use in the field of blood coagulation |
Abstract: | The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described. |
Inventor(s): | Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE) |
Assignee: | Bayer HealthCare AG (Leverkusen, DE) |
Application Number: | 10/181,051 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,157,456 |
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,157,456
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | XARELTO | rivaroxaban | FOR SUSPENSION;ORAL | 215859-001 | Dec 20, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-004 | Oct 11, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-001 | Jul 1, 2011 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-002 | Nov 4, 2011 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,157,456
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Germany | 199 62 924 | Dec 24, 1999 |
PCT Information | |||
PCT Filed | December 11, 2000 | PCT Application Number: | PCT/EP00/12492 |
PCT Publication Date: | July 05, 2001 | PCT Publication Number: | WO01/47919 |
International Family Members for US Patent 7,157,456
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 032436 | See Plans and Pricing | |||
Austria | 289605 | See Plans and Pricing | |||
Australia | 2004218729 | See Plans and Pricing | |||
Australia | 2841401 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |